
The strongest independent predictor of SCC metastasis
DecisionDx-SCC provides an independent risk of metastasis score as well as identifies patients likely to benefit from adjuvant radiation therapy (ART).
New publication in Future Oncology confirms DecisionDx-SCC identifies high-risk SCC patients who benefit most from adjuvant radiation therapy
DecisionDx-SCC has now been independently validated to predict ART treatment benefit in two studies comprising over 1,300 patients. Together, these two studies by Ruiz et al. in Future Oncology (2024) and Arron et al. in the Red Journal (2024) represent the largest published population of ART-treated high-risk SCC patients. Results from this study provide a validation of the performance of the previously reported (Arron et al. Red Journal 2024) benefit of ART for Class 2B tumors and a lack of benefit for Class 1 tumors and was conducted using 423 tumors from 399 patients from Brigham Women’s Health (BWH) and Cleveland Clinic. Given the consistency of the results from two independent cohorts, DecisionDx-SCC can aid in ART decision-making for patients with high-risk SCC tumors.

Key findings
New publication Red Journal shows DecisionDx-SCC identifies high-risk squamous cell carcinoma patients who are likely to benefit from adjuvant radiation therapy and those who can consider deferring treatment based on biological risk of metastasis
Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma and Specification of Benefit of Adjuvant Radiation Therapy
In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher metastasis-free survival (MFS) rates, on average, and slowed disease progression compared to Class 2B patients who did not receive ART.
Patients with Class 1 test results, predicted to have a lower risk of metastasis, did not see an improvement in survival after receiving ART, which together indicates these patients may be able to avoid the treatment.to non-ART treated patients. In addition, in patients with a Class 1 (lower risk) test result there was a non-significant benefit from ART treatment.